Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.…
Bicara Therapeutics (BCAX) Stock Gets Fair Value Trim As Analysts Split On Ficera
Bicara Therapeutics (NASDAQ: BCAX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 103 employees.
The shares were at 8.440 USD on 20 November 2026, down 44.4% over 52 weeks. Its 52-week range is 7.870 USD to 30.99 USD: the price is 72.8% below the high and 7.2% above the low.
Its market capitalisation is 560.31M USD.
Bicara Therapeutics reports return on equity of -34.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 441.47M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Buy; their mean price target of 32.17 USD is 281.1% above the current price. The next earnings report is expected on 29 March 2027.